Biotech Stock News (CLVS)(SNTA)

Clovis Oncology (NASDAQ:CLVS) On Tuesday April 13, 2016 Clovis Oncology announced that the FDA advisory panel concluded that the company’s drug, Rociletinib, had insufficient data to warrant approval. Not only did the FDA panel advise against approval, it shot down the drug with a vote of 12 “against and 1 “for” approval. This was the … Read more

Biotech Stock News (AGN) (PFE) (ICPT)

Allergan (NYSE:ACT) & Pfizer (NYSE:PFE) On April 5, 2016 shares of Allergan had tumbled by 14.77% as investors had become skeptical that the deal with Pfizer would actually go through. The reason for ¬†investors becoming skeptical was because the government had implemented new tax inversion rules. Back in November Pfizer brokered a deal to buy … Read more

Biotech Stock News (RPTP) (AERI) (CANF)

Raptor Pharmaceuticals (NASDAQ:RPTP) On Monday September 14, 2015 shares of Raptor Pharmaceuticals ended the day down 38% after the company announced that it had failed a phase 2b liver study in children with NASH — non-alcoholic steatohepatitis. The phase 2b trial enrolled up to 169 children with NASH between the ages of eight and seventeen. … Read more

Biotech Stock News (RGLS)(AZN)(INO)(TKMR)

Regulus Therapeutics (NASDAQ:RGLS) & AstraZeneca (NYSE:AZN)¬† On April 7, 2015 Shares of Regulus were up about 8% in after hours trading after the company reported that Astrazeneca would like to collaborate with the company to develop a NASH drug. NASH stands for non-alcoholic steatohepatitis and as the name suggests it is a disease that doesn’t … Read more

Biotech Stock News (RXII) (MRK) (BMY) (CNAT) (ICPT)

Rxi Pharmaceuticals Corp (NASDAQ: RXII) Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported ¬†positive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. … Read more